Background {#Sec1}
==========

Acute kidney injury (AKI) is a life-threatening disease and global health burdens with increasing incidence in both developed and developing countries \[[@CR1], [@CR2]\]. AKI commonly occurs in the intensive care unit (ICU), and is caused by multiple risk factors, leading to adverse clinical outcomes, increasing costs, and the development of chronic kidney disease (CKD) \[[@CR3]--[@CR8]\]. The definition of AKI has evolved from the Risk, Injury, Failure, Loss, End-stage (RIFLE) criteria and the AKI Network (AKIN) classification to the Kidney Disease Improving Global Outcomes (KDIGO) classification \[[@CR9]--[@CR11]\]. A multinational epidemiological study using KDIGO criteria showed that the incidence of AKI in the ICU was 57.3% \[[@CR12]\], which implies concern regarding AKI the in ICU globally with extremely high morbidity reported. It is essential for physicians, researchers, and health policy makers to establish an accurate incidence of AKI \[[@CR12]\]. There have been were large epidemiological studies of patients hospitalized with AKI in the Chinese population \[[@CR13], [@CR14]\]. However, there have been limited epidemiological data on AKI in the ICU in mainland China reported \[[@CR15]\]. Therefore we performed a cohort study of all the adult patients in 30 ICUs of 28 hospitals in Beijing to determine the incidence, risk factors, renal replacement therapy (RRT) practice, and the outcome of patients with AKI.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a multi-center prospective cohort study on the epidemiology of AKI in ICU patients in Beijing, China. A full list of the participating hospitals is provided in Additional file [1](#MOESM1){ref-type="media"}. The study was registered with the Chinese Clinical Trial Registry (ChiCTR-ONC-11001875). Thirty ICUs in 28 teaching hospitals (two of the hospitals include two ICUs, respectively) in Beijing participated in this prospective observational study between March 1, 2012, and August 31, 2012 (a 6-month period). The Ethics Committee of Capital Medical University, Fuxing Hospital and all other participating hospitals approved the informed consent waiver due to the anonymous and non-interventional nature of the study (2010FXHEC-KY026, Additional file [2](#MOESM2){ref-type="media"}). Patients admitted to any participating ICU during the study period were included. We excluded (1) patients under 18 years old, (2) undergoing any kind of RRT within 3 months, (3) kidney transplantation within 3 months, (4) anticipated length of stay in the ICU (ICU-LOS) for less than 24 h, and (5) readmission to the ICU during the study period.

Definitions {#Sec4}
-----------

AKI was defined by the KDIGO criteria \[[@CR16]\]. Patients were categorized on the basis of serum creatinine and/or urine output; the criteria leading to the worst classification used. Baseline serum creatinine was defined as the lowest serum level during the preceding 3 months \[[@CR17]\]. For patients without a baseline serum creatinine laboratory test result, the baseline was estimated by the modification of diet in renal disease (MDRD) equation and customized for the Chinese population, assuming a glomerular filtration rate (GFR) of 75 mL/min per 1.73 m^2^ \[[@CR18]\]. Sepsis was defined as the combination of infection and systemic inflammatory response syndrome \[[@CR19]\].

Data collection {#Sec5}
---------------

Data were recorded on the case-reported form (CRF) (Additional file [3](#MOESM3){ref-type="media"}). On admission, data regarding demographics, admission time point, in-hospital location before ICU admission, acute physiology age and chronic health evaluation II (APACHE II) score, simplified acute physiology score II (SAPS II) score, sequential organ failure assessment (SOFA) score, baseline serum creatinine, comorbidity, and medications administrated before ICU admission were collected. During the first 10 days after admission, daily vital signs, urine output per hour, daily fluid balance, serum creatinine, medications, interventions, possible causes for AKI, diagnosis and stage of AKI, detailed information of RRT including reasons for initiation of RRT, mode of RRT, and anticoagulant and dilution patterns were collected. Diagnosis of sepsis and association between sepsis and AKI were reported. Outcome measures were collected including mortality, ICU-LOS, costs, withholding or withdrawal of life-sustaining treatments (WH/WD), and RRT dependence on the 7th and 28th days.

Statistical analyses {#Sec6}
--------------------

Continuous variables are presented as medians with interquartile ranges (IQRs), and compared by the Mann-Whitney U-test or Kruskal-Wallis ANOVA test. Categorical variables were compared using either the chi-square test or Fisher's exact test when appropriate. Statistical descriptions and tests above were performed using SPSS version 17.0.1 (SPSS Inc., Chicago, IL, USA). Multivariable logistic regression with odds ratio (OR) and 95% confidence interval (CI) was performed to assess independent risk factors for AKI development. Cox proportional hazards regression analysis with hazard ratio (HR) and 95% CI was performed to examine whether the KDIGO stage was associated with mortality adjustment for baseline severity of illness, age and other factors. We used weighted estimators corresponding to each covariate derived from the fited logistic and Cox regression coefficients. The prognostic index was calculated by summing the number of risk points corresponding to each weighted covariate used to build the two nomograms. The specific codes used are provided in Additional file [4](#MOESM4){ref-type="media"}: Appendix 4. A *p* value of less than 0.05 was considered significant. The nomograms of logistic regression and Cox regression were performed using R 3.5.1. The function "lrm" of the package "rms" was used for the logistic regression. The function "cph" of the package "survival" was used for the Cox regression.

Results {#Sec7}
=======

A total of 3107 participants were included in the final analysis among the 9049 patients admitted to the participating ICUs during the study period. The flow chart is presented in Fig. [1](#Fig1){ref-type="fig"}. In comparison of the characteristics between patients with and without AKI, patients with AKI have a higher median age, baseline serum creatinine, APACHE II score, SAPS II score, SOFA score, non-renal SOFA score, more comorbidity, a higher rate of mechanical ventilation, use of inotropic agents and diuretics, and WH/WD. (Table [1](#Tab1){ref-type="table"}). Fig. 1Flow chart. *AKI* acute kidney injury, *KDIGO* Kidney Disease: Improving Global Outcomes, *RRT* renal replacement therapy Table 1Characteristics and outcomes of included patientsAll patientsAKINon-AKI*p*Number of patients3107 (100%)1584 (50.9%)1523 (49.1%)Age (years)64 (51--77)67 (53--78)62(49--74)\< 0.001Male1912 (61.5%)970 (61.2%)942 (61.9%)0.74Baseline SCr77 (60.2--93)79 (63--94)74 (58.8--89)\< 0.001APACHE II score14 (10--20)17 (12--23)12 (8--16)\< 0.001SAPS II score34 (26--45)39 (30--52)29 (23--38)\< 0.001SOFA score6 (3--8)7 (4--10)4 (2--7)\< 0.001Non-renal SOFA score5 (3--8)6 (4--9)4 (2--6)\< 0.001Co-morbidity CHD615 (19.8%)370 (23.4%)245 (16.1%)\< 0.001 CHF (NYHA IV)217 (7.0%)152 (9.6%)65 (4.3%)\< 0.001 HT1222 (39.3%)687 (43.4%)535 (35.1%)\< 0.001 DM532 (17.1%)320 (20.2%)212 (13.9%)\< 0.001 COPD166 (5.3%)98 (6.2%)68 (4.5%)0.038 CKD203 (6.5%)167 (10.5%)36 (2.4%)\< 0.001 CLF91 (2.9%)53 (3.3%)38 (2.5%)0.168Sources of patients ED774 (24.9%)440 (27.8%)334 (21.9%)\< 0.001 general wards586 (18.9%)383 (24.2%)203 (13.3%)\< 0.001 post-operation1627 (52.4%)692 (43.7%)935 (61.4%)\< 0.001 other ICUs31 (1.0%)21 (1.3%)10 (0.7%)\< 0.001 other hospitals89 (2.9%)48 (3.0%)41 (2.7%)\< 0.001Medications before admission Aminoglycosides47 (1.5%)30 (1.9%)17 (1.1%)0.079 Glycopeptide antibiotics50 (1.6%)32 (2.0%)18 (1.2%)0.065 Radio-contrast media560 (18%)305 (19.3%)255 (16.7%)0.069 Mannitol92 (3.0%)45 (2.8%)47 (3.1%)0.751 NSAIDs253 (8.1%)152 (9.6%)101 (6.6%)0.003 ACEI/ARB523 (16.8%)281 (17.1%)242 (15.9%)0.179 Statin352 (11.3%)184 (11.6%)168 (11.0%)0.611 SCr83 (62--116)105.4 (72--161)70.8 (56.7--89)\< 0.001 Sepsis641 (20.6%)459 (29.0%)182 (12.0%)\< 0.001Organ failure Respiratory failure811 (26.1%)538 (34.0%)273(17.9%)\< 0.001 Acute hepatic failure53 (1.7%)37 (2.3%)16 (1.1%)0.006 Hematologic failure44 (1.4%)34 (2.1%)10 (0.7%)\< 0.001 Shock484(15.6%)353(22.3%)131 (8.6%)\< 0.001 Cardiogenic shock117 (3.8%)96 (6.1%)21 (1.4%)\< 0.001 Hypovolemic shock201 (6.5%)130 (8.2%)71 (4.7%)0.004 Septic shock222 (7.1%)173 (10.9%)49 (3.2%)\< 0.001 Obstructive shock4 (0.1%)2 (0.1%)2 (0.1%)\< 0.001 MV2344 (75.4%)1260 (79.5%)1084 (71.2%)\< 0.001 Vasopressors930 (29.9%)480 (30.3%)450 (29.5%)0.666 Inotropic agents665 (21.4%)366 (23.1%)299 (19.6%)0.02 Diuretics1650 (53.1%)1067 (67.4%)583 (38.3%)\< 0.001 WH/WD691 (22.2%)398 (25.1%)293 (19.2%)\< 0.001 ICU mortality395 (12.7%)346 (21.8%)49 (3.2%)\< 0.001 28-day mortality542 (17.4%)438 (27.7%)104 (6.8%)\< 0.001 ICU-LOS (days)4(2--10)5.5 (3--11)3 (2--6)\< 0.001 ICU overall costs (RMB)32,000 (17000--74,000)42,000(21000--95,000)26,000 (14000--51,000)\< 0.001 ICU daily costs (RMB)6500 (4500--10,000)6667 (4826--10,182)6333 (4333--10,000)\< 0.001Values are presented as n (proportion) or median (interquartile range)*AKI* Acute kidney injury, *SCr* Serum creatinine, *CHD* Coronary heart disease, *CHF* Chronic heart failure, *NYHA* the New York heart association functional classification, *HT* Hypertension, *DM* Diabetes mellitus, *COPD* Chronic obstructive pulmonary disease, *CKD* Chronic kidney disease, *CLF* Chronic liver failure, *APACHE II* Acute physiology and chronic health evaluation II, *SAPS II* Simplified acute physiology score II, *SOFA* Sequential organ failure assessment score non-renal, *SOFA* Sequential organ failure assessment score without the renal component, *ED* Emergency department, *ICU* Intensive care unit, *NSAIDs* Non-steroidal antiinflammatory drugs, *ACEI* Angiotensin-converting enzyme inhibitor, *ARB* Angiotensin receptor blocker, *MV* Mechanical ventilation, *WH/WD* Withholding or withdrawal of life-sustaining therapy

Incidence of AKI {#Sec8}
----------------

The incidence of AKI was 51.0% (1584 of 3107) including stage 1 AKI 23.1% (718 of 3107), stage 2 AKI 11.8% (368 of 3107), and stage 3 AKI 15.7% (498 of 3107) (Fig. [1](#Fig1){ref-type="fig"}). The majority of patients with AKI (87.6%, 1388 of 1584) developed AKI during the first 4 days after admission to the ICU (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Daily AKI onset and accumulative AKI patients on the first 10 days. *No*. number, *AKI* acute kidney injury, *CRF* case report form, *KDIGO* the Kidney Disease: Improving Global Outcomes

Causes and risk factors of AKI {#Sec9}
------------------------------

Hypovolemia (25.4%), sepsis on ICU admission (22.2%) and low cardiac output (20.5%) were the top three possible causes. The logistic regression nomogram indicated that baseline creatinine (OR = 1.00; 95% CI 1.00--1.01), APACHE II score (OR = 1.05; 95% CI: 1.04--1.07), SOFA score (OR = 1.16; 95% CI 1.13--1.19), sepsis (OR = 1.88; 95% CI 1.56--2.27) and exposure to nephrotoxic drugs (OR = 1.41; 95% CI 1.19--1.66) might be independent predictors of AKI development (Fig. [3](#Fig3){ref-type="fig"}a). There were 876 patients diagnosed with sepsis on ICU admission and/or during ICU stays. Physicians reported that 296 (33.8%) cases of sepsis contributed to AKI, and 175 (20.0%) cases of sepsis were possibly associated with AKI development. Fig. 3Nomogram of independent predictors for development of AKI and 28 day mortality. Each predictor with a given value can be mapped to the Points axis. The sum of these points can be referred to in the Total Points axis. Then the linear predictor and the probability of development of AKI (A) and survival (B) can be obtained from corresponding axis. The green bar indicates the 0.7 confidence limits for each score, and the short red bar corresponds to 0.1 confidence limits. *Cr* baseline creatinine, *APACHE* acute physiology and chronic health evaluation II, *SOFA* sequential organ failure assessment score, *Drugs* nephrotoxic drug exposure, KDIGO Kidney Disease: Improving Global Outcomes criteria and stage of AKI, *28-day sur.pro* probability of survival on the 28th day

Renal replacement therapy {#Sec10}
-------------------------

A total of 281 patients were treated with RRT, including 270 patients with AKI (accounting for 17% of the AKI and 8.7% of all patients) and 11 non-AKI patients. The top four reasons to initiate RRT were anuria/oliguria (71.9%, 201/281), severe metabolic acidosis (25.6%, 72/281), hyperkalemia (21.7%, 61/281) and fluid overload (20.3%,57/281). Furthermore, 38.3% (109 of 281) of patients had multiple reasons for initiating RRT, with anuria/oliguria together with hyperkalemia being most commonly reported. The 11 non-AKI patients received RRT due to acute heart failure (*n* = 4, to reduce heart load), poisoning (*n* = 3, to detoxify), heat stroke (*n* = 2, for rapid hypothermia), and sever e sepsis (n = 2, to clear inflammatory media). The characteristics and outcomes of RRT patients are presented in Table [2](#Tab2){ref-type="table"}. The majority of RRT procedures were continuous RRT (CRRT). Intermittent RRT (IRRT) was seldom used (2%). Continuous veno-venous hemofiltration (CVVH) was the most common mode. Among 277 patients with the modes of anticoagulant reported, sodium citrate (121, 43.7%) was the most commonly reported anticoagulation pattern, followed by no anticoagulation (68, 24.5%), unfractionated heparin (53, 19.1%) and low-molecular-weight heparin (22, 7.9%). For dilution patterns reported in 269 cases, predilution, combination of pre- and post-dilution, and postdilution accounted for 56.5, 25.3, and 18.2%, respectively. Of the 284 reported catheter insertion sites, the femoral vein was the most common (74.3%, 211/284; with 125 right femoral vein, 86 left femoral vein), followed by the internal jugular vein (23.6%, 67/284; with 48 right jugular vein, 19 left jugular vein), 5 subclavian vein and 1 arterio-venous fistula. Continuous RRT with predilution, citrate for anticoagulation and femoral vein for vascular access was the most common pattern (29.9%, 84 of 281). For adverse events, bleeding or oozing at the catheterization site was the most commonly reported (12.5%, 35 of 281), followed by gastrointestinal bleeding (9.6%, 27 of 281) and cutaneous bruise or ecchymoses (6.8%, 19 of 281). The 28-day mortality of patients treated with RRT was 48.8%. In 281 patients treated with RRT, 76.0% (173 of 220 survivors) of patients depended on RRT on the 7th day. Among 144 survivors on the 28th day, 41 patients (28.5%) were dependent on RRT; 25 (19.7%) patients depended on intermittent hemodialysis (IHD), and 16 (11.1%) depended on CRRT. The ICU-LOS, mortality rate and costs of RRT patients were significantly higher than those of non-RRT AKI patients (Table [2](#Tab2){ref-type="table"}). Table 2Characteristics and outcomes of RRT patientsRRTNon-RRT*P*Number of patients2811314Characteristics Age66 (52--79)67 (53--78)0.141 Male178 (63.3%)791 (60.2%)\<0.05 APACHE II22 (17--29)16 (11--22)\<0.05 ICU mortality109 (38.8%)236 (17.9%)\<0.05 28-day mortality130 (46.3%)303 (23.0%)\<0.05 ICU-LOS (days)8 (5--17)5 (3--10)\<0.05 ICU overall costs (RMB)104,000 (60000--213,000)37,000 (19000--87,000)\<0.05 ICU daily costs (RMB)9765 (5580--14,625)6143 (4333--9000)\<0.05 RRT dependent on 7th day173/220 (78.6%)NR\<0.05 RRT dependent on 28th day41/144 (28.5%)NR\<0.05*APACHE II* Acute physiology and chronic health evaluation II, *ICU* Intensive care unit, *LOS* Length of stay, *NR* Not recorded, *RRT* Renal replacement therapy

Clinical outcomes and costs {#Sec11}
---------------------------

Patients with AKI had a significantly higher rate of withholding or withdrawing of life-sustaining treatments, ICU mortality, 28-day mortality, longer ICU-LOS, and higher ICU overall costs (Table [1](#Tab1){ref-type="table"}). The 28-day mortality rate of non-AKI patients was 6.83%. The mortality rates of AKI stages 1--3 were 15.04, 27.99, and 45.18%, respectively. The 28-day mortality rate of the 917 septic AKI patients was 36.5%. The Cox regression nomogram indicated that a higher stage of AKI (HR = 1.35; 95% CI 1.25--1.47), higher age (HR = 1.01; 95% CI 1.01--1.02), high APACHE II (HR = 1.03; 95% CI 1.02--1.05) and SOFA scores (HR = 1.03; 95% CI 1.00--1.06), and sepsis (HR = 1.63; 95% CI1.35--1.98) were independent predictors of mortality (Fig. [3](#Fig3){ref-type="fig"}b).

Discussion {#Sec12}
==========

Our results indicated a high incidence of AKI in the ICU. Approximately half of our ICU patients experienced AKI. The incidence in the present study was significantly higher than those in an international epidemiological study in 2005 \[[@CR20]\] and the FINNAKI study \[[@CR21]\], which might be attributed to the discrepancy in diagnostic criteria. A study comparing the three diagnostic criteria indicated that the KDIGO criteria identified more patients with AKI and were more predictive of short-term mortality \[[@CR22]\]. The incidence in the present study was similar to the Acute Kidney Injury- Epidemiological Prospective Investigation (AKI-EPI) study \[[@CR12]\]. The AKI-EPI study \[[@CR12]\] was the first multinational epidemiological study in the ICU using the KDIGO criteria. Both AKI-EPI and our study demonstrated an unsatisfactory prevention and increasing burden of AKI. In our study, the top three possible causes reported by physicians were hypovolemia, sepsis on ICU admission and low cardiac output, which was similar to the result of the FINNAKI study (preceding AKI severe sepsis, pre-ICU hypovolemia and pre-ICU hypotension) \[[@CR21]\]. Our logistic regression showed comprehensible risk factors. The RRT ratio in our study was similar to that of the FINNAKI study (8.6% vs 9.4%) \[[@CR21]\], but lower than that of the AKI-EPI study (13.5%) \[[@CR12]\]. The higher RRT ratio in the AKI-EPI study could be attributable to the higher ratio (KDIGO stage 3: 30.0%) of patients with more severe AKI in comparison with the other two studies (KDIGO stage 3: 15.7%; AKIN stage 3: 14.1%). The RRT pattern results indicated that CRRT was mainly chosen (97.9%) and that IRRT was seldom used. A previous observational study in French ICUs showed that 40% of RRT patients had CRRT and 60% had IRRT \[[@CR23]\], which varied greatly from our results. Although the previous studies have shown no difference in clinical outcomes comparing CRRT and IRRT in the ICU \[[@CR24]--[@CR26]\], our results revealed a strong inclination to CRRT in our ICUs. The advantages of CRRT include better hemodynamic tolerance, accurate balance control and better clearance of the middle molecule \[[@CR11], [@CR27]\]. Besides our ICU physicians and nurses were familiar with CRRT and unfamiliar with IRRT. Our results showed that the femoral vein (74.6%) was the most common catheter location, differing from the recommendations in the guideline (the right internal jugular vein) \[[@CR28]\]. Studies have suggested that the internal jugular vein might be preferable to the femoral vein to minimize dialysis catheter dysfunction and blood recirculation to improve RRT provision and reduce the risk of infection \[[@CR29]--[@CR32]\]. The reasons for our physicians preferring femoral access might be the advantages of convenience, efficiency and fewer complications in the operating procedure. The results indicated that citrate was the most commonly used for anticoagulant. Meta-analyses \[[@CR33]--[@CR35]\] suggested that citrate is preferable to heparin in anticoagulation for CRRT to prolong circuit life span, reduce the risk of bleeding \[[@CR34], [@CR35]\], and increase the delivered RRT dose \[[@CR33]\]. Citrate is novel and has not been used for long in CRRT; nevertheless, our results indicated that it has already been widely used in Beijing. However, considering the advantages of better medical resources in Beijing, the capital city of China, the result may not be representative of the whole country. The distinction of guideline compliance with respect to vascular access and anticoagulation might imply that changes in medication are more acceptable for physicians than are changes in techniques. The mortality rate was comparable to the FINNAKI study \[[@CR21]\]. The regression analysis indicated that a greater severity of AKI, and comorbidity of sepsis were associated with an increased risk of mortality, which was in accordance with the previous studies \[[@CR12], [@CR13], [@CR21]\]. Our results showed a significantly higher ICU costs for RRT patients, which is reasonable and comparable to other studies \[[@CR26], [@CR35]\]. RRT patients had a higher AKI stage, more complications, higher disease severity score and longer ICU-LOS, all of which lead to higher costs \[[@CR35]\]. Our results showed that increased AKI stage and septic AKI were associated with higher mortality, and those trends were also found in a study that evaluated patients with AKI with and without sepsis \[[@CR36]\]. More than 1/4 of survivors were RRT dependent, which would lead to heavy burdens. There are strengths in our study. This is the first large, prospective, multicenter cohort study of AKI in the ICU in Beijing. We used the KDIGO criteria to evaluate the prevalence of AKI. Previous studies \[[@CR22], [@CR37], [@CR38]\] indicated that the KDIGO criteria defined more patients with AKI in comparison with RIFLE and AKIN. Further analysis showed that the patients missed by RIFLE had higher mortality rate and longer hospital-LOS than the patients missed by KDIGO \[[@CR22]\]. For the first time the incidence of AKI in the ICU for ten consecutive days was reported, to the best of our knowledge. The results revealed an obvious downtrend of AKI onset over time. We consider this result to be meaningful epidemiological data that might imply the necessity of key vigilance against the risk of AKI in the first 4 days after ICU admission. Furthermore, we investigated the comprehensive situation in RRT practice. Thus, we understood our insufficiencies and underlying causes, which are important areas for policy makers and physicians to make improvements. There were limitations in our study. First, our participating hospitals were all located in Beijing. As the capital city of China, Beijing enjoys better medical resources. Thus, the results of our study might not be representative of hospitals nationwide. Second, we used the MDRD equation to estimate the baseline serum creatinine for missing values, as recommended \[[@CR18], [@CR39]\]. However, the MDRD method may result in under- or overestimation of baseline creatinine \[[@CR39], [@CR40]\]. Third, we screened patients for AKI for the first 10 days after admission to the ICU. Thus, we were unable to analyze later-onset AKI. However, based on our results, the majority of patients with AKI (87.6%) had AKI onset in the first 4 days after admission. Our data on the occurrence of AKI during the first 10 days may imply that the onset of AKI in the ICU decreases over time, and new onset after 10 days would be minimal.

Conclusions {#Sec13}
===========

There was a high incidence of AKI in the ICU. Approximately half of our ICU patients experienced AKI. The majority of patients with AKI developed AKI during the first four ICU days. For RRT patterns, continuous RRT, predilution, citrate, and femoral vein were the most commonly used RRT procedure, dilution mode, anticoagulant and vascular access, respectively. AKI was associated with increased mortality and costs, incomplete kidney recovery and a series of adverse outcomes. Higher AKI stage, septic-AKI and the need for RRT were associated with increased mortality.
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AKI

:   Acute Kidney Injury

AKIN

:   Acute Kidney Injury Network

APACHE II

:   Acute Physiology Age and Chronic Health Evaluation II

CI
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CKD

:   Chronic Kidney Disease

CRF

:   Case Reported Form

CRRT

:   Continuous Renal Replacement Therapy

CVVH

:   Continuous Veno-Venous Hemofiltration
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:   Glomerular Filtration Rate
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ICU

:   Intensive Care Unit

IHD

:   Intermittent Hemodialysis
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IRRT

:   Intermittent Renal Replacement Therapy

KDIGO

:   Kidney Disease Improving Global Outcomes

LOS

:   Length Of Stay
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:   Modification of Diet in Renal Disease
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RIFLE

:   Risk, Injury, Failure, Loss, End-stage

RRT

:   Renal Replacement Therapy

SAPS II

:   Simplified Acute Physiology Score II
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WH/WD

:   Withholding or Withdrawal of Life-sustaining Treatments
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